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CObjective: Therapeutic interchange is not a common practice in the
medical society in Asia. We used clinic blood pressure readings, patients’
tolerance, and cost saving as measures to evaluate the impact of a thera-
peutic interchange program implemented at a medical center in Taiwan.
Methods: Taipei Medical University-Wan Fang Hospital initiated a ther-
apeutic interchange program involving angiotensin II receptor blockers
(ARBs). Data were retrospectively collected for 444 outpatients who were
converted from other ARBs to candesartan. Evaluation of therapeutic effi-
cacy, adverse effects associated with therapy, and drug costs was conducted
before and after the program implementation. Results: Patients whose
treatment was converted to candesartan experienced no statistically sig-
nificant differences in blood pressure, and the average number of antihy- O
e no
harm
al So
doi:10.1016/j.jval.2011.11.001ertensive agents used per patient remained unchanged. A direct cost
avings of US$62,237 was estimated for the 444 patients studied. Only
.15% of the patients developed adverse drug reactions potentially related
o candesartan, and none required hospitalization. Conclusions: Based
n the results of this retrospective chart review, the present ARB thera-
eutic interchange program was successfully developed and imple-
ented. This is the first study to establish the positive impact of a well-
un ARB therapeutic interchange program in Taiwan.
eywords: angiotensin II receptor blockers, candesartan, hypertension,
herapeutic interchange.
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utcomes Research (ISPOR). Published by Elsevier Inc.Background
A well-managed hospital formulary system has been recog-
nized as the most effective method to ensure that medically
appropriate and cost-effective drugs are available for use within
an institution [1,2]. The American Society of Hospital Pharma-
cists guidelines for formulary system management recommend
that the Pharmacy and Therapeutics (P&T) Committee review
the use and therapeutic effects of several drug classes each year
[3]. After identifying the preferred agents within a pharmaco-
logical class, the P&T Committee can execute therapeutic inter-
change to substitute more expensive agents with less expensive
ones while maintaining equal efficacy [4]. A survey in 2000 es-
timated that more than 80% of US hospitals had therapeutic
interchange programs mostly involving H2-receptor antago-
nists, proton pump inhibitors, cephalosporins, hydroxymethyl-
glutaryl-coenzyme A reductase inhibitors, and so on [5]. This
strategy has been used to effectively manage a variety of ther-
apeutic classes in hospital systems in the United States [6 –10].
Therapeutic interchange has not been a commonly accepted
medical practice in Taiwan. Under the influence of aggressive pro-
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Published by Elsevier Inc.motion by pharmaceutical companies, physicians generally be-
lieve that patients respond differently to each drug in the same
therapeutic class. In addition, most prescription medications on
the market are covered by Taiwan’s National Health Insurance, a
single-payer nationwide insurance plan instituted in March 1995.
The National Health Insurance enrolled 97.6% of the population by
2004 and increased the enrollment to 99.6% in 2009. It covers in-
patient care, ambulatory care, dental care, and prescription med-
ications with very low co-payments, usually around 5% to 10% of
medication costs, for both brand-name and generic products. The
National Health Insurance reimburses all brand-name drugs
within the same therapeutic class with the same price at their
equivalent doses and generics with 70% to 80% of the price of the
brand-name products. It is not easy to persuade patients to switch
their medications within the same therapeutic class, because they
misunderstand that the hospitals were changing their brand-
name drugs to generic ones. Many of our patients do not believe that
the domestic generic version of a brand-name prescription drug is as
good as the foreign imported one. As a result, it was commonplace
for a hospital in Taiwan to have a formulary with more than 1000
drugs and many “me-too” agents in a therapeutic class.
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S112 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) S 1 1 1 – S 1 1 5In 2004, the health-care system of Taipei Medical University
(TMU) successfully replaced a significant number of trade-name
prescription drugs with therapeutic equivalents on the formulary,
which was truly revolutionary in Taiwan. A Joint P&T Committee
was established in 1986 at TMU’s health-care system, which con-
sisted of TMU Hospital and TMU–Wan Fang Hospital (TMU-WFH),
for managing the formulary system. A Pharmacy Management
Group, consisting of several clinical pharmacists and pharmacy
managers from both the teaching hospitals and a pharmacist con-
sultant from the United States, was established in 2004 by adapt-
ing the principles from the American Society of Hospital Pharma-
cists’ formulary management guidelines to promote rational drug
use. The Pharmacy Management Group reviews both quarterly
and yearly 80/20 reports (ranked by pharmaceutical costs) to iden-
tify potential areas for clinical and financial interventions. In 2004,
cardiovascular agents accounted for about 30% of the total drug
costs based on the first quarter 80/20 report. Angiotensin II recep-
tor blocker (ARB), accounting for 7.5% of total drug expenditures as
the top therapeutic class, was determined by the P&T Committee
as a potential class for the first therapeutic interchange program at
TMU-WFH.
ARBs have been used commonly for the treatment of hyperten-
sion, heart failure, myocardial infarction complicated by heart
failure, and diabetic nephropathy. In Taiwan, this therapeutic
class accounts for more than one-third of the market share for
antihypertensive agents. It is the second most used antihyperten-
sive drug class after calcium channel blockers. The use of ARBs has
been included in many clinical practice guidelines, such as the
Seventh Report of the Joint National Committee on Prevention,
Detection, Evaluation, and Treatment of High Blood Pressure,
guidelines of the American College of Cardiology/American Heart
Association regarding the management of patients with heart fail-
ure or following myocardial infarction, and guidelines published
by the Kidney Disease Outcomes Quality Initiative of the National
Kidney Foundation [11–13]. The National Quality Foundation in Au-
gust 2009 also endorsed the medication possession ratios for angio-
tensin-converting-enzyme inhibitor or ARB by patients with chronic
kidney disease or diabetes and hypertension as one of the standards
for measuring the performance of health-care providers [14]. All
ARBs are approved for the treatment of hypertension, and some have
also been approved for other conditions, such as treating heart fail-
ure, treating myocardial infarction complicated by left ventricular
dysfunction, or use in diabetic patients with nephropathy. Currently,
there are no significant clinical advantages in terms of efficacy or
risks that justify the use of one ARB over another [15–17].
A therapeutic interchange program involving ARBs was initiated
at TMU-WFH, a 732-bed medical center, in May 2004, after being ap-
proved by the Joint P&T Committee of TMU health-care system. To
our knowledge, this was the first therapeutic interchange program
implemented in Taiwan. The objective of this study was to evaluate
the impact of the therapeutic interchange program in WFH on pa-
tients’ blood pressure control and cost saving.
Methods
Initiation of therapeutic interchange program
Four ARBs—valsartan (Diovan
®
, Novartis, Taiwan), irbesartan
(Aprovel
®
, Sanofi-Aventis, Taiwan), telmisartan (Micardis
®
, Boehr-
inger Ingelheim, Taiwan), and a combination of losartan and hy-
drochlorothiazide (Cozaar
®
, Merck, Taiwan)—were originally in-
luded in the TMU-WFH formulary. Using our formulary decision
riteria, the P&T Committee decided to limit the ARBs on the for-
ulary to candesartan and valsartan in 2004. The TMU’s formu-
ary decision criteria, which were similar to the System of Objec-
ified Judgment Analysis, included appropriate indications, factors
ffecting patient compliance, bioavailability, interactions, clinicalmpact and efficacy, acquisition cost, and documentation support-
ng efficacy [18,19]. Candesartan was listed as the preferred agent
ith a high score in the formulary decision criteria due to its low
cquisition cost and good documentation for hypertension, and
alsartan was restricted to patients with heart failure. A dosage
onversion guide was developed by referring to multiple clinical
ead-to-head comparison trials involving ARBs [20–23], and the
uide was approved by the Joint P&T Committee at TMU health-
are system in August 2004. The use of candesartan increased over
ime, and it accounted for more than 75% of the ARB market share as
f October 2004. After the Food and Drug Administration approved
andesartan for the treatment of heart failure (New York Heart As-
ociation classes II–IV and ejection fraction40%) in 2005, the score
f candesartan became the highest among ARBs in our formulary
ecision criteria. As a result, the Joint P&T Committee decided to
emove valsartan and listed candesartan as the sole formulary ARB
n May 2005.
Study design and subjects
A total of 899 patients with active prescriptions for candesartan
were identified in the computerized outpatient database during
the period of October 4–9, 2004. Medical records of these patients
were made available for initial review. Inclusion criteria were hy-
pertensive patients switched from other ARBs to candesartan dur-
ing the study period. Exclusion criteria included 1) hospitalization
during the study period not because of ARB-induced adverse drug
reaction (ADR), 2) diagnosis of cancer, 3) younger than 18 years of
age, 4) use of candesartan prior to the implementation of the ther-
apeutic interchange program, and 5) incomplete blood pressure
documentation. Incomplete blood pressure documentation was
defined as having fewer than two blood pressure readings in the
patient’s medical records within 6 months before or after conver-
sion. It is a standard practice in Taiwan to prescribe a 3-month
refilled prescription to patients who have chronic diseases stably
controlled by medications. Patients visit the doctor’s office only
every 3 months, unless there is any unusual condition, such as
experienced new clinical signs/symptoms or any side effects. Ex-
cluding the patients with fewer than two blood pressure readings
would not exclude the patients experiencing unwanted effects
from the ARB switching program.
The data collected included patient demographics, pertinent di-
agnoses, blood pressure readings, and number of antihypertensive
agents used per patient within 6 months pre- and postconversion, as
well as any ADRs, such as headache, dizziness, angioedema, or in-
creased serum potassium occurring in the postconversion period. To
measure the number of patients who were successfully converted
from their original treatment, the number of patients who discontin-
ued angiotensin II receptor therapy within 1-year postconversion
was also calculated. Cost savings from implementing this therapeu-
tic interchange program for each patient was calculated by using the
following formula:
Table 1 – Reasons patients were excluded from current
study.
Number of
patients
Reason
Hospitalization during the study period 14
Patients with cancer 7
Use of candesartan before the therapeutic
interchange program implementation
5
Incomplete blood pressure documentation 202
Total 228
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S113V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) S 1 1 1 – S 1 1 5Yearly cost saved [(Acquisition cost of initial ARB
daily dose of initial ARB) (Acquisition cost of candesartan
daily dose of candesartan)] 30 days 12 months
Data analysis
We compared average blood pressure readings before and after con-
versions with paired t test. A sample size of 67 patients was neces-
sary to achieve 80% power to detect a mean SD difference of 4.7
13.5 mm Hg in systolic blood pressure. A sample size of 254 patients
was determined to have 80% power to detect a mean SD difference
of 1.3  7.4 mm Hg in diastolic blood pressure. The number of anti-
hypertensive agents prescribed and the cost of ARBs per patient be-
fore and after the conversion were also analyzed with paired t test. A
P value of less than 0.05 was considered significant. Statistical anal-
ysis was performed by using SPSS 10.0 (SPSS, Inc., Chicago, IL).
Results
Of the 899 patients with active candesartan prescriptions, 672 met
the inclusion criteria. There were 150 patients not on any ARB before
program implementation and candesartan was the only ARB they
have used, and there were 77 patients using an ARB for indications
other than hypertension. We further excluded another 228 patients
according to the exclusion criteria and thus left 444 patients for the
final chart review (Table 1). Table 2 details the demographic charac-
teristics of study subjects. The mean age was 6812 years in patients
switched to candesartan. Of the 444 patients using candesartan post-
conversion, 220 (49.5%) were females and 224 (50.5%) were males.
Two hundred and eleven had concomitant diseases, including 112
(25%) patients with diabetes mellitus, 70 (16%) patients with heart
failure, and 29 (7%) patients with both diabetes and heart failure.
The average times of blood pressure readings were 5.5  0.67 in
the study subjects. For patients converted to candesartan, the differ-
ence between preconversion and postconversion blood pressure
readings was not statistically significant (Table 3). The antihyperten-
sive regimen besides ARBs changed after the therapeutic inter-
change in only 55 patients (12.4%). The average number of antihyper-
Table 2 – Demographics of patients included in chart
review.
Characteristic
Age (y) 67.99  12.09
Gender, n (%)
Men 224 (50.5)
Women 220 (49.5)
Concomitant conditions, n (%)
Diabetes 112 (25)
CHF 70 (16)
Diabetes and CHF 29 (7)
CHF, congestive heart failure.
Table 3 – Comparison before and after conversion to cande
Before
Systolic blood pressure (mm Hg) 138.
Diastolic blood pressure (mm Hg) 80.
Number of antihypertensive agents 2.
Mean monthly cost of ARBs per patient (US$) 20.ARBs, angiotensin-receptor blockers.tensive agents was 2.08 per patient before conversion to candesartan
and 2.10 per patient after the conversion. The difference was statis-
tically insignificant (P 0.54). Cost savings here were expressed in US
ollars. The exchange rate of New Taiwanese dollar to US dollar in
004 was around 33.9. The mean monthly cost for ARBs per patient
as US$20.89  8.0 and US$9.21  3.2 before and after drug conver-
ion, respectively. The difference was statistically significant, with a
value of less than 0.001. The estimated annual direct drug cost
aving as a result of this P&T Committee–approved therapeutic in-
erchange program was US$62,237 for the 444 patients studied. The
edication cost differences in 55 patients who experienced antihy-
ertensive regimen change were neglected here because they re-
ulted in a total increase of only US$1.7.
ADRs were screened via chart review and voluntary reporting
ystem. Of the 444 patients, 14 (3.15%) patients developed ADRs that
ould potentially be related to candesartan and underwent a change
n therapy during the postconversion period. Seven patients com-
lained of dizziness or headache, two patients had gastrointestinal
iscomfort, two patients developed cough, and three patients had
eneral complaints, such as drowsiness or general discomfort, with-
ut further evaluation (Table 4). No ADRs requiring hospitalization
ere identified from the review of medical records. A total of 119
atients discontinued using candesartan within 1 year. Four patients
ho died within a year of drug conversion were excluded from this
ssessment. The overall discontinuation rate was 26.8%. Only 3.2% of
atients discontinued treatment with candesartan because of ad-
erse effects. Other reasons for not continuing treatment with can-
esartan included therapy deemed unnecessary, suboptimal blood
ressure control, and patient’s request. For more than 50% of the
atients who discontinued taking the drug within 1 year after con-
ersion, no reason was clearly specified, however.
Discussion
The present study is, to the best of our knowledge, the first success-
fully implemented therapeutic interchange program with significant
economic outcomes in Taiwan. Although other therapeutic inter-
change programs involving ARBs have been described in Western
countries, the concept is still controversial and has not yet been
widely adopted in Taiwan and in other Asian countries [24,25]. The
results proved that ARB therapeutic interchange can be effectively
implemented for cost-savings purpose without compromising ef-
ficacy or increasing toxicity in this setting. There was no statisti-
cally significant difference in average blood pressure readings and
an.
ersion After conversion P value
13.89 139.85  14.40 0.054
9.62 81.40  9.95 0.201
0.88 2.10  0.88 0.54
8.0 9.21  3.2 0.001
Table 4 – Adverse drug reactions potentially related to
candesartan.
Adverse drug reaction Number (%) of observations
Headache/dizziness 7 (1.58)
Gastrointestinal complaints 2 (0.45)
Cough 2 (0.45)
General complaints 3 (0.68)
Total 14 (3.15)sart
conv
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S114 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) S 1 1 1 – S 1 1 5the number of antihypertensive agents used before and after the
conversion.
The most significant aspect of this program is the substantial
direct drug cost savings. A total of US$ 62,237 per year in savings
was calculated over the cost of using the original ARBs for the 444
patients studied. With more than 5200 patients in the hospital-
dispensing database using ARBs each month, the cost savings
have been more than US$730,000 annually, and nearly US$3 mil-
lion from 2005 to 2008. The study demonstrates that therapeutic
interchange, by using a replacement drug with similar clinical ef-
fectiveness, can significantly save the cost of pharmacotherapy
while maintaining the high quality of service.
The study findings were in accord with results from other West-
ern studies relating to similar ARB therapeutic interchange programs
[24,25]. The results indicated that therapy conversion did not signif-
icantly affect blood pressure control among outpatients. The inci-
dence of ADRs related to the switch was low (3.15%), and none of the
ADRs required hospitalization or led to life-threatening conditions.
Overall, the formulary ARB, candesartan, was effective in controlling
PMG generates quar
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Clinical team in PMG performs 
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Fig. 1 – Process recommended for implementing a successblood pressure and well tolerated. Other studies report that success- cful therapeutic interchange was possible in 78% to 79% of patients on
ARBs or other antihypertensive agents, which was similar to our ob-
servation, accounting for the patients who discontinued candesartan
within 1 year of conversion [24–26]. The study also interestingly
ound that discontinuation of therapy after drug conversion was at-
ributable not only to adverse drug effects, but patients’ perceptions
f the conversion program or other factors within the operation pro-
ess could also influence the discontinuation rate. With continuous
ommunication to the prescribers and patients to change the cul-
ural belief, future programs may result in a more satisfying outcome
ith respect to the decision to discontinue treatment.
The study demonstrated a model of initiating and executing ther-
peutic interchange program in a society where therapeutic inter-
hange is far from a common practice and acceptable clinical con-
ept. Figure 1 provides suggestions to program planners on what to
o to successfully implement a therapeutic interchange program in
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S115V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) S 1 1 1 – S 1 1 5to make the formulary decision. More importantly, involving the ma-
jor prescribers in the decision-making process is crucial. To change
the cultural hypothesis of high variation on patients’ responses to
“me-too” drugs, pharmacy has to provide structural interview, per-
form focus group discussion, and deliver in-service education ses-
sions to elucidate the unbiased evidence. Finally, with the strong
support from the administration, the executive director could per-
sonally communicate with physicians who were highly resistant to
the program according to the weekly report of market share. With all
the above efforts, the number of ARBs on the formulary in TMU-WFH
was gradually decreased from four to one over almost 1 year.
There are several limitations in the study. The retrospective de-
sign heavily relied on the quality of medical charts. The accuracy of
blood pressure recordings and ADR data in charts could affect the
evaluation. The most common reason for excluding patients from
the study was a lack of documented blood pressure readings on med-
ical charts. This limited the number of patients who were reviewed.
Other factors such as patients’ compliance were not well docu-
mented in the charts. Although only a small number of patients dis-
continued candesartan because of side effects, the reasons for dis-
continuation were usually difficult to detect by chart review. Another
study surveying patients or prescribers would be needed to under-
stand the rationales for drug discontinuation and develop strategies
to improve future therapeutic interchange programs in the hospital.
The intent of the study was not to prove the long-term treatment
outcomes of ARBs. We looked at blood pressure control only as the
indicator for therapeutic efficacy.
Conclusions
The present therapeutic interchange program for ARBs in TMU-
WFH is a model of successful pharmacy intervention and medica-
tion cost-containment in Taiwan. It is practical for health-care
institutions to select a few preferred medications in the same ther-
apeutic class without undermining the patient’s benefit. Stopping
the masquerade by the me-too drugs can contain the medication
cost for more necessary medical conditions.
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